[Latest] Global Mushroom Market Size/Share Worth USD 146,912.1 Million by 2033 at a 10.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
13 juin 2024 14h40 HE
|
Custom Market Insights
Austin, TX, USA, June 14, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Mushroom Market Size, Trends and Insights By Type of Mushroom (Button Mushrooms,...
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
13 juin 2024 11h39 HE
|
Spherix Global Insights
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are...
Investment Opportunity: PlantForm Corporation Seeks $25M to Accelerate Plant-Based Medical Breakthroughs
12 juin 2024 14h40 HE
|
US Capital Global
San Francisco, California, USA, June 12, 2024 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an SEC-registered affiliate of renowned global financial group US Capital Global, is pleased to...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024
12 juin 2024 14h19 HE
|
Sanofi - Aventis Groupe
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
Sanofi: Information concerning the total number of voting rights and shares – May 2024
12 juin 2024 14h19 HE
|
Sanofi - Aventis Groupe
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
The World Market for Oral Solid Dosage Forms (OSDF) and Pharma Excipients, 2024-2030
11 juin 2024 11h23 HE
|
Research and Markets
Dublin, June 11, 2024 (GLOBE NEWSWIRE) -- The "Oral Solid Dosage Forms (OSDF) and Pharma Excipients - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's...
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
11 juin 2024 06h00 HE
|
NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel...
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma
11 juin 2024 02h00 HE
|
Essential Pharma
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma Egham, UK and Copenhagen,...
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
11 juin 2024 01h00 HE
|
NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing...
Working with Emotional Intelligence in the Pharmaceutical and Biopharma Industry: 1-Day Online Training Course (October 14, 2024) with Theory, Activities, Exercises, and Practical Applications
10 juin 2024 09h38 HE
|
Research and Markets
Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Working with Emotional Intelligence in the Pharmaceutical and Biopharma Industry Training Course" conference has been added to ...